- Home
- XGN vs FBRX Comparison
XGN vs FBRX Comparison
Compare XGN & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XGN
- FBRX
- Stock Information
- Founded
- XGN 2002
- FBRX N/A
- Country
- XGN United States
- FBRX United States
- Employees
- XGN N/A
- FBRX N/A
- Industry
- XGN Medical Specialities
- FBRX Biotechnology: Pharmaceutical Preparations
- Sector
- XGN Health Care
- FBRX Health Care
- Exchange
- XGN Nasdaq
- FBRX Nasdaq
- Market Cap
- XGN 138.3M
- FBRX 154.5M
- IPO Year
- XGN 2019
- FBRX N/A
- Fundamental
- Price
- XGN $7.27
- FBRX $11.60
- Analyst Decision
- XGN Strong Buy
- FBRX Strong Buy
- Analyst Count
- XGN 3
- FBRX 2
- Target Price
- XGN $9.00
- FBRX $61.00
- AVG Volume (30 Days)
- XGN 272.4K
- FBRX 73.6K
- Earning Date
- XGN 07-29-2025
- FBRX 08-13-2025
- Dividend Yield
- XGN N/A
- FBRX N/A
- EPS Growth
- XGN N/A
- FBRX N/A
- EPS
- XGN N/A
- FBRX N/A
- Revenue
- XGN $56,724,000.00
- FBRX N/A
- Revenue This Year
- XGN $18.92
- FBRX N/A
- Revenue Next Year
- XGN $14.78
- FBRX N/A
- P/E Ratio
- XGN N/A
- FBRX N/A
- Revenue Growth
- XGN 1.78
- FBRX N/A
- 52 Week Low
- XGN $1.78
- FBRX $4.11
- 52 Week High
- XGN $7.95
- FBRX $28.68
- Technical
- Relative Strength Index (RSI)
- XGN 56.94
- FBRX 53.91
- Support Level
- XGN $6.81
- FBRX $10.02
- Resistance Level
- XGN $7.50
- FBRX $10.99
- Average True Range (ATR)
- XGN 0.33
- FBRX 0.86
- MACD
- XGN 0.02
- FBRX -0.06
- Stochastic Oscillator
- XGN 75.27
- FBRX 60.78
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).